Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2025 | The efficacy of extracorporeal photopheresis for the treatment of steroid-refractory chronic GvHD

Dennis Kim, MD, PhD, Princess Margaret Cancer Centre, Toronto, Canada, briefly discusses the efficacy of extracorporeal photopheresis (ECP) as a treatment for steroid-refractory chronic graft-versus-host disease (GvHD). Dr Kim highlights that, although ECP is highly effective as monotherapy, combining it with other treatments can further enhance the response rate and improve patient outcomes. This interview took place at the 51st Annual Meeting of the EBMT in Florence, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Yeah, so I think that there is also a very important topic because ECP treatment is one of the very effective treatment modalities in our current GvHD patient. And another thing is that it doesn’t have any drug-drug interactions. So it is not only an effective treatment modality for our current GvHD treatment option, but also it can enhance their response rate and it can improve their outcome when we combine it with other treatments...

Yeah, so I think that there is also a very important topic because ECP treatment is one of the very effective treatment modalities in our current GvHD patient. And another thing is that it doesn’t have any drug-drug interactions. So it is not only an effective treatment modality for our current GvHD treatment option, but also it can enhance their response rate and it can improve their outcome when we combine it with other treatments. By itself as a monotherapy it is effective and it is very very feasible, however there is a potential that you can combine it with other treatment modalities.

 

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Disclosures

Honoraria: Sanofi, Novartis, Astellas, Pfizer, Sankyo-Daichi, Jazz.